An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Condition
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Empagliflozin/linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
Most Recent Events
- 22 Apr 2025 New trial record